Pharmaceutical composition for use in medical and veterinary ophthalmology

1. A method of treating an eye pathology, comprising administering to a subject afflicted with such an eye pathology a therapeutically-effective amount of a pharmaceutical composition comprising:

(a) from 1 nm to 25000 nm of a mitochondria-addressed antioxidant comprising:

(b) from 0.01% to 0.2% of a lipophilic, cationic concentration stabilizer that stabilizes a concentration of the mitochondria-addressed antioxidant by preventing reversible and irreversible absorption of the antioxidant to walls of a vial containing the pharmaceutical composition, the stabilizer comprising a benzalkonium salt, berberine, palmatine, tetraphenylphosphonium, tetrabutyl ammonium, or combinations thereof; and

(c) from 0.001% to 1% of a prolongator comprising a disaccharide, a trisaccharide, a polysaccharide, methylcellulose, hydroxyethylcellulose, hydroxypropyl-methyl cellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, carboxyvinyl polymer, polyvinyl ethanol, polyvinylpyrrolidone, macrogol, or combinations thereof.

2. The method of claim 1 , wherein the eye pathology is macular degeneration of the retina.

3. The method of claim 1 , wherein the eye pathology is cataract, senile cataract and/or diabetic cataract.

4. The method of claim 1 , wherein the eye pathology is a retinopathy.

5. The method of claim 4 , wherein the retinopathy is retinal detachment, detached retinal vessels, detached choroid, optic nerve retinopathy, optic nerve atrophy, central and peripheral chorioretinal dystrophies, or uveitis.

6. The method of claim 1 , wherein the eye pathology is intraocular hemorrhage or traumatic hemorrhage.

7. The method of claim 1 , wherein the eye pathology is conjunctivitis, eye ulcer, keratitis, or dry keratoconjunctivitis.

8. The method of claim 1 , wherein the eye pathology is glaucoma.